Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri maintains an Overweight rating on SI-BONE (NASDAQ:SIBN) but lowers the price target from $25 to $21.
July 15, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley analyst Drew Ranieri maintains an Overweight rating on SI-BONE but lowers the price target from $25 to $21.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100